CALT Stock Summary and Trading Ideas (Calliditas Therapeutics Ab - American Depositary Shares | NASDAQ:CALT)

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics Ab - American Depositary Shares trades on the NASDAQ stock market under the symbol CALT.

As of May 21, 2024, CALT stock price declined to $21.50 with 3,801 million shares trading.

CALT has a market cap of $576.98 million. This is considered a Small Cap stock.

Last quarter Calliditas Therapeutics Ab - American Depositary Shares reported $42 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.01.

In the last 3 years, CALT stock traded as high as $33.19 and as low as $10.82.

The top ETF exchange traded funds that CALT belongs to (by Net Assets): APIE, DFIS, DFIC.

CALT has underperformed the market in the last year with a return of +9.8%, while the SPY ETF gained +28.5%. In the last 3 month period, CALT fell short of the market, returning +2.8%, while SPY returned +7.3%. However, in the most recent 2 weeks CALT has outperformed the stock market by returning +6.8%, while SPY returned +2.9%.

CALT support price is $20.63 and resistance is $23.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CALT stock will trade within this expected range on the day.